Morgan Stanley Takes a Look at Abiomed's Future

According to a research report published today, Morgan Stanley says Abiomed's ABMD future appears challenging due to near term catalysts. Morgan Stanley commented in the report, “Increasing the pace of additions in response to heightened demand and opportunities presented by hospital year end budgeting appears defensible. But, Abiomed's “go deeper” strategy has done a good job of driving utilization and we expect center adds to revert to ~25 per qr. If reorder weakness does not prove transient, this strategy could become challenged.” Morgan Stanley maintains its Equal weight rating on Abiomed, which closed Friday at $20.98.